No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Hold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial Outlook
Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript
Immunic | 10-Q: Quarterly report
Express News | Immunic Says It Bolstered Balance Sheet Through Three-tranche Private Placement Totaling Up To $240M, Extending Cash Runway Into Q3 2025, Based On Initial $80M Tranche
Immunic: Q1 Earnings Snapshot
Express News | Immunic Q1 EPS $(0.30) Misses $(0.26) Estimate, Cash And Equivalents As Of March 31, 2024 Were $97.3M
No Data